Date: October 9, 2024
Time: 9:00am PDT, 11:00am CDT, 12:00pm EDT
In the fast-paced world of healthcare-associated infections (HAIs) management, time is of the essence. Traditional diagnostic techniques, which can take days to yield results, often lead to challenges such as inefficient patient and bed management, increased isolation costs, and higher laboratory workloads. The growing threat of carbapenem-non-susceptible Gram-negative organisms, characterized by their high mortality rates and the potential for widespread transmission, further complicates the challenge. The KPC, VIM, NDM, OXA-48 and IMP carbapenemase genes are some of the most frequently identified that confer carbapenem resistance, but emerging genes, such as OXA-23, pose a challenge in diagnostic testing with the currently available methods.
Join us for an insightful webinar where two esteemed clinical microbiologists from Brazil and France will provide their perspectives and share their expertise on integrating molecular techniques for CPO (carbapenemase-producing organism) screening. Discover how these advanced methods can enhance diagnostic stewardship efforts within antimicrobial stewardship programs, streamline lab practices, and improve patient management.
Learning Objectives
- Evaluate the emerging threats and key risk factors driving the spread of multidrug-resistant organisms (MDROs).
- Harness molecular screening techniques to transform laboratory practices and drive effective diagnostic stewardship.
- Explore the critical impact of rapid negative results reporting on clinical decision-making and patient outcomes.
- Navigate the complex challenges in detecting emerging enzymes in resistant organisms.
Webinars will be available for unlimited on-demand viewing after live event.